Haga Bioscience AB

Based in Sweden, Haga Bioscience AB specializes in advanced spatial omics technologies that deliver precise solutions for biomarker validation in research and clinical settings. Haga Bioscience AB operates in the field of spatial omics, making strides in RNA detection technology. Founded in 2024 in Sweden, the company has completed 1 deal, with its most recent funding round occurring on June 3, 2026. The company raised SEK 20.

9 million in a SEED round, which is also the total amount raised to date. The founder's history or previous ventures are not specified, nor does the company appear to have any subsidiaries. Haga Bioscience specializes in advanced spatial omics technologies focused on in situ RNA detection, providing precise solutions for biomarker validation in real tissue samples. The company's core product offerings include HAGA Pattern, enabling single-cell resolution RNA detection; HAGA Point, which detects single-nucleotide mutations at the same resolution; and HAGA Panorama, allowing for 10-plex RNA detection within a single imaging round.

These technologies are designed to address significant challenges in translating tissue biology discoveries into actionable biomarkers, enabling researchers to validate candidate biomarkers across large patient cohorts with scalable workflows. Haga Bioscience serves a diverse customer base, including academic institutions, clinical research organizations, and pathology labs primarily within Europe and North America. Haga Bioscience generates revenue through direct transactions with clients in the research and clinical sectors, focusing on B2B partnerships and institutional sales. The company’s offerings, such as the HAGA Pattern and HAGA Panorama products, are provided under structured agreements that enable laboratories to integrate these advanced technologies into their workflows.

Clients enter contracts for product purchases, potentially coupled with ongoing technical support and training services, allowing institutions to adopt Haga's technologies for large-scale biomarker validation and tissue analysis, ensuring consistent performance across various research settings. In June 2026, Haga Bioscience AB raised SEK 20. 9 million in Seed funding from unspecified investors. The company intends to leverage this funding to further develop its RNA Analysis Technology.

Future growth plans include the design and launch of new products aimed at enhancing its existing offerings, with specific release dates yet to be determined. Additionally, Haga Bioscience aims to expand its market presence within Europe and North America, enhancing accessibility to its solutions for a wider range of researchers and clinicians.